An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
Brief description of study
The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just osimertinib itself. The combination of the two medications is investigational. Al investigational medication or drug is one that has not been approved by the U.S. Food & Drug Administration (FDA).
Clinical Study Identifier: s18-01922
ClinicalTrials.gov Identifier: NCT03909334
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
